OncoMed Pharmaceuticals Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
OncoMed Pharmaceuticals (OMED) PT Raised to $16 at Jefferies
August 10, 2016 8:31 AM EDTJefferies analyst Brian Abrahams reiterated a Buy rating and boosted his price target on OncoMed Pharmaceuticals (NASDAQ: OMED) to $16.00 (from $15.00) following Q2 update.
Abrahams commented, "OMED will have multiple data updates in 2H16/1H17 as well as potential opt-in catalysts from collaborators. We... More
OncoMed Pharma (OMED) Misses Q2 EPS by 10c
August 9, 2016 5:09 PM EDTOncoMed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.91), $0.10 worse than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $8.09 million.
For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.
... More